These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18241288)

  • 1. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events.
    Boersma C; Postma MJ; Visser ST; Atthobari J; de Jong PE; de Jong-van den Berg LT; Gansevoort RT;
    Br J Clin Pharmacol; 2008 May; 65(5):723-32. PubMed ID: 18241288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
    Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):645-654. PubMed ID: 35878651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria:
    Chang AR; Kramer H; Wei G; Boucher R; Grams ME; Berlowitz D; Bhatt U; Cohen DL; Drawz P; Punzi H; Freedman BI; Haley W; Hawfield A; Horwitz E; McLouth C; Morisky D; Papademetriou V; Rocco MV; Wall B; Weiner DE; Zias A; Beddhu S;
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1121-1128. PubMed ID: 32669306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events.
    Özyilmaz A; Bakker SJ; de Zeeuw D; de Jong PE; Gansevoort RT;
    Nephrol Dial Transplant; 2013 Nov; 28(11):2805-15. PubMed ID: 23975751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
    Vogt L; Navis G; Köster J; Manolis AJ; Reid JL; de Zeeuw D;
    J Hypertens; 2005 Nov; 23(11):2055-61. PubMed ID: 16208149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
    Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microalbuminuria and urinary albumin excretion: French clinical practice guidelines.
    Halimi JM; Hadjadj S; Aboyans V; Allaert FA; Artigou JY; Beaufils M; Berrut G; Fauvel JP; Gin H; Nitenberg A; Renversez JC; Rusch E; Valensi P; Cordonnier D
    Diabetes Metab; 2007 Sep; 33(4):303-9. PubMed ID: 17702622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis.
    Pinho-Gomes AC; Azevedo L; Copland E; Canoy D; Nazarzadeh M; Ramakrishnan R; Berge E; Sundström J; Kotecha D; Woodward M; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    PLoS Med; 2021 Jun; 18(6):e1003599. PubMed ID: 34061831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis.
    Viazzi F; Muiesan ML; Schillaci G; Salvetti M; Pucci G; Bonino B; Signori A; Pontremoli R
    J Hypertens; 2016 Sep; 34(9):1689-97. PubMed ID: 27254313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.
    Galceran J; Plana J; Felip A; Pou G; Vila J; Sobrino J
    Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):751-7. PubMed ID: 20528630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Microalbuminuria and urinary albumin excretion: clinical practice guidelines].
    Halimi JM; Hadjadj S; Aboyans V; Allaert FA; Artigou JY; Beaufils M; Berrut G; Fauvel JP; Gin H; Nitenberg A; Renversez JC; Rusch E; Valensi P; Cordonnier D
    Nephrol Ther; 2007 Oct; 3(6):384-91. PubMed ID: 17919641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse pressure monitoring of open antihypertensive therapy.
    Safar ME; Vaisse B; Blacher J; Rudnichi A; Mourad JJ
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1088-94. PubMed ID: 15607613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.